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Abstract
Background:   Good  prescribing practice  has  an important part to  play  in  the  fight  against
antimicrobial  resistance.  Whilst  it  was  perceived  that  most  hospitals  and  Health  Authorities
possessed  an  antibiotic  policy,  a  review  of  antibiotic  policies  was  conducted  to  gain  an
understanding of the extent, quality and usefulness of these policies.
Methods:  Letters were sent to pharmacists in hospitals and health authorities in across the South
East region of the National Health Service Executive (NHSE) requesting antibiotic policies. data
were extracted from the policies to assess four areas; antibiotic specific, condition specific, patient
specific issues and underpinning evidence.
Results:   Of a possible  41 hospital trusts  and 14 health authorities, 33 trusts and  9 health
authorities (HAs) provided policies. Both trust and HA policies had a median publication date of
1998 (trust range 1993-99, HA 1994-99). Eleven policies were undated. The majority of policies
had no supporting references for the statements made. All policies provided some details on
specific antibiotics. Gentamicin and ciprofloxacin were the preferred aminoglycoside and quinolone
respectively with cephalosporins being represented by cefuroxime or cefotaxime in trusts and
cephradine  or  cephalexin  in  HAs.  26  trusts  provided  advice  on  surgical  prophylaxis,  17  had
meningococcal  prophylaxis  policies  and  11  covered  methicillin  resistant  Staphylococcus  aureus
(MRSA). There was little information for certain groups such as neonates or children, the pregnant
or the elderly.
Conclusion:  There was considerable variation in content and quality across policies, a clear lack
of an evidence base and a need to revise policies in line with current recommendations.
Background
In the United Kingdom, concerns around resistance to
antibiotics have been expressed for some time, leading to
a House of Lords select committee report [1], a report
from the Standing Medical Advisory Committee (SMAC)
[2] and a subsequent Health Service Circular [3] setting
out a course of action for the National Health Service.
The Health Service Circular (HSC) was based on four el-
ements of strategy, surveillance, prudent antibiotic use,
and infection control. These concerns focussed on the
need to treat patients on the one hand but not to so com-
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promise the environment that there is no effective treat-
ment for certain infections.
In the HSC, Regional Directors of Public Health were
tasked to lead the work addressing the problem of anti-
microbial resistance with colleagues who were the Re-
gional Epidemiologists and the Regional Prescribing
Leads. Regional Prescribing Leads were asked 'to identi-
fy good prescribing practice in the use of antimicrobials'
and to ensure that information in widely disseminated
among those who are involved in prescribing antimicro-
bials.
This project was undertaken to review one of the long-
standing measures for encouraging good practice and
controlling antibiotic use: the antibiotic policy, i.e. guid-
ance or instruction on when and how antimicrobial
drugs are to be used [1]. The primary aim was to gain in-
sight into the use of antibiotic policies as a mechanism to
encourage good, evidence-based, practice and facilitate
the appropriate use of antimicrobials. The advice provid-
ed in the policies was assessed against recognised best
practice [4].
Methods
The South East region of the NHSE had 14 health author-
ities within which there were a total of 41 NHS trusts pro-
viding hospital and/or community care. Letters were
sent in June 1999 to the Chief Pharmacists of the NHS
trusts and the Pharmaceutical Advisers of the Health Au-
thorities requesting their antibiotic policies. Those which
did not respond were followed up by up to two telephone
calls.
The authors selected four sets of features for the assess-
ment of the policies based around the current guidance
[1,2,3]: antibiotic specific issues, a set of conditions to
which policies might apply, a set of patient groups who
might have special mention in a policy such as neonates
or pregnant women. Reference to underpinning evi-
dence for the statements made was sought. The authors
formed an opinion of the presentation and user-friendli-
ness of each policy from how easy it was for them, com-
ing new to each policy, to find information. Each set of
features was broken down into a series of specific items
of advice or information that users might seek in the pol-
icies. These items were considered to be important
enough to be included in the policies.
The data were extracted by one author (PJW) and
checked by the other (RTMW). Discrepancies were dis-
cussed and a consensus reached. Anonymised data for all
responses was sent back to Trusts and Health Authorities
with a code enabling them to identify their own data.
Perceived errors in data extraction were reported back
and discussed with the authors. A workshop was held in
January 2000 for microbiologists and pharmacists in the
region to discuss the findings of this work and the devel-
opment of future policies.
Results
Thirty-three trusts and nine health authorities provided
their policies. There were two groups of trusts (one group
with two trusts and one with three) that shared policies,
so there were 39 policies to review. Eight trusts did not
provide a policy, one teaching trust provided two policies
covering three sites, and one HA provided policies for
three trusts which were planning to merge. One Mental
Health Trust uses its HA policy which, like other HA pol-
icies, was written for patients outside acute hospitals.
The trust policies were focussed on the needs of patients
in acute hospitals.
The trusts and health authorities that sent in their anti-
biotic policies were distributed across the whole region.
The region had been created in 1999 from parts of three
other NHSE regions (Anglia-Oxford, South Thames and
South-West). There was no association of non-respond-
ents with their former NHS regions. As far as the authors
could determine, the non-respondents did not have cur-
rent antibiotic policies, rather than refusing to submit
their policies to independent review.
The policies provided had a wide range of presentation
styles ranging from an interactive computer programme
to a single folded card. The most popular formats were
A4 (11 policies), pocket size, including filofax (12 poli-
cies) or A5 (11 policies) the remainder being in mixed for-
mat or unusual sizes. One trust (the Winchester &
Eastleigh NHS Trust) used an electronic format with its
policy on the hospital intranet, from which a complex set
of printouts, based on a decision analysis process, were
supplied for the review.
Trust policies had a median publication date of 1998
(range 1993-99) and Health Authority policies also had a
median publication date of 1998 (range 94-99). Policies
from eight Trusts and three Health Authorities were un-
dated.
The level of information in Trust policies suggested that
most policies were written for junior hospital doctors but
this was not generally explicit. Policies from Health Au-
thorities were intended for general practitioners. It was
not clear if most policies were advisory or mandatory;
the only three policies to include a statement on this said
that they were advisory. Fourteen of the trust policies
and four of the Health Authority policies provided at
least one contact telephone number for advice.BMC Public Health (2001) 1:4 http://www.biomedcentral.com/1471-2458/1/4
Only two of policies contained references to support
their statements (one reference each). At the workshop
to discuss the review, the comment was made that refer-
ences might make the policies to large to carry in the
pocket.
Antibiotic Specific Issues
All policies provided some details on specific antibiotics
and the majority (34 out of 41) provided some advice on
length of treatment, although this advice was sparse in
five of the 34. Fifteen Trusts and five Health Authorities
policies provided information on side effects, and con-
traindications but the advice was often not clearly ex-
pressed, lacking in detail and specificity.
In terms of the drugs of choice, gentamicin was the fa-
voured aminoglycoside where mentioned and cipro-
floxacin the favoured quinolone. The cephalosporin
group showed a range with cefuroxime and cefotaxime
being more popular than cephalexin and ceftriaxone in
trusts. Cephradine and/or cephalexin (both oral) were
recommended by eight out of nine Health Authorities in
their guidance for general practice.
Conditions Specific Policies
All the Trust policies and most (eight out of nine)of the
Health Authority policies recommended treatment for
specific conditions.
Trust policies
Prophylaxis
Twenty-seven Trust policies provided advice on surgical
prophylaxis policies. There was wide variation in the
number of regimens (Table 1), from a trust with one rec-
ommendation to two Trusts had twenty prophylaxis reg-
imens each specific for different types of surgery. Five
Trusts did not have a stated policy despite having surgi-
cal departments.
Meningococcal prophylaxis was in the policies of 17
Trusts, and the remaining Trusts either have no policy or
referred the reader to the British National Formulary.
Fifteen Trusts did not have an explicit policy for antibiot-
ic prophylaxis after splenectomy and three Trusts did not
recommend a treatment period for post splenectomy an-
tibiotic prophylaxis.
Lower respiratory tract infections
The majority of Trusts favoured amoxicillin for bronchi-
tis, either as the only recommendation (11 trusts) or as
one of two or three choices (13 trusts). Erythromycin, tri-
methoprim, doxycyline, tetracycline and benzylpenicil-
lin were also recommended. Seven Trusts have no stated
policy for treating bronchitis (Table 2). Amoxicillin or
ampicillin was most frequently recommended as a treat-
ment for pneumonia, followed by the cephalosporins and
benzyl penicillin (table 3). Seven other antibiotics ap-
peared one or more times.
Table 1: Numbers of surgical prophylactic regimens in NHS 
trusts
Numbers of different regimens recom-
mended in the trust
Number of trusts
1- 5 4
5-10 9
11-15 8
16-20 3
Each department has own regimen 3
No stated policy 5
Total 32
(a psychiatric hospital was excluded from this analysis)
Table 2: Antibiotics recommended for bronchitis
Antibiotic Hospital 
Trusts
Health 
Authorities
Amoxicillin alone 12 2
Amoxicillin with alternatives 13 5
Co-amoxiclav (amoxicillin with 1 0
clavulanic acid) or tetracycline
No policy 7 2
Total 33 9
Table 3: Antibiotics recommended for pneumonia
Antibiotic Hospital 
Trusts
Health 
Authorities
Ampicillin/Amoxicillin alone 3 0
Amoxicillin and/or erythromycin 5 7
Ampicillin/Amoxicillin with other 5 1
alternatives
Benzylpenicillin 8 0
Cephalosporins 10 0
Co-amoxiclav 2 0
No policy 0 1
Total 33 9BMC Public Health (2001) 1:4 http://www.biomedcentral.com/1471-2458/1/4
Urinary Tract Infections
Trimethoprim was recommended for cystitis in twenty-
eight Trusts (Table 4), but only fifteen restricted the
choice to trimethoprim or another specific urinary anti-
microbial (nitrofurantoin). Nitrofurantoin was given as
an alternative to trimethoprim by six Trusts. Three trusts
gave cephalosporins as the first line treatment for cystitis
and 13 suggested broad spectrum antibiotics as a alter-
native to trimethoprim. One policy said that antibiotics
were not normally indicated for cystitis.
Only 18 Trust policies made recommendations on treat-
ing pyelonephritis and severe urinary tract infections.
Injectable cephalosporins were the preferred treatment.
Amoxicillin, ciprofloxacin and gentamicin were also
mentioned.
Diarrhoeal Diseases
In the policies which covered gastro-enteritis, it was rec-
ommended in 17 trusts that no antibiotic treatment be
given for most patients, whether there was a known
pathogen or not. Ciprofloxacin was listed a treatment for
more severe cases in two Trust policies. Twelve Trust
policies did not cover gastro-enteritis. For the treatment
of C. difficile infection, 14 Trusts advised metronidazole,
three advised oral vancomycin and three said that either
were suitable.
MRSA
Eleven policies cover the issue of MRSA. The advice
ranged from a brief mention to a lengthy document cov-
ering a wide range of issues about the treatment of carri-
ers and infected patients
Health Authority Policies
Prophylaxis
Meningococcal prophylaxis (rifampicin for two days)
was described by four of the nine Health Authorities. A
fifth health authority recommended contacting the Con-
sultant in Communicable Disease Control (CCDC), i.e.
the public health physician responsible for controlling
infection in the area covered by the health authority.
Only one Health Authority mentioned splenectomy
prophylaxis, recommending penicillin or erythromycin
for at least two years.
Lower respiratory tract infections
Amoxicillin was most frequently recommended drug for
bronchitis (Table 2) with alternatives as cefaclor, tetracy-
clines or erythromycin. For pneumonia treated by gener-
al practitioners, amoxicillin and erythromycin were
treatments most frequently mentioned (Table 3).
Urinary Tract Infections
For cystitis, all Health Authorities favoured trimetho-
prim with alternatives as nitrofurantoin, cephalosprorin
or co-amoxiclav (amoxicillin plus clavulanic acid). Simi-
lar treatments were recommended for pyelonephritis,
but one Health Authority recommended ciprofloxacin as
the first choice (Table 5).
Diarrhoeal Diseases
All Health Authorities that included a section that stated
antibiotics were not generally recommended. The five
Health Authorities that mentioned C. difficile favoured
metronidazole.
Patient Specific Policies
Generally, there were no policies for neonates or children
although some policies included a few neonatal or paedi-
atric doses. Two Trusts did provide guidelines for those
groups. There were no policies for the elderly and little
advice on antibiotics in pregnancy.
Table 4: Antibiotics recommended for cystitis
Antibiotic Hospital 
Trusts
Health 
Authorities
Trimethoprim 13 2
Trimethoprim or nitrofurantoin 2 1
Trimethoprim or a cephalosporin 7 4
Trimethoprim or another broad 6 1
spectrum
Cephalosporins first 3 0
Antibiotic not indicated 1 0
No policy 1 1
Total 33 9
Table 5: Antibiotics recommended for pyelonephritis
Antibiotic Hospital 
Trusts
Health 
Authorities
Ampicillin/Amoxicillin plus another 3 0
antibiotic
Cephalosporins 14 0
Trimethoprim or other antibiotic 0 4
Ciprofloxacin 1 1
No specific policy 15 4BMC Public Health (2001) 1:4 http://www.biomedcentral.com/1471-2458/1/4
Workshop Issues
The main feature of the workshop was to discuss key el-
ements of antibiotic policy production and maintenance.
There was a perception of a lack of quality evidence to
underpin policy decisions and implementation with a
concern that an evidence base be worked up centrally to
the benefit of all. There was consensus that the grade of
evidence supporting a particular statement be indicated
in the policy document. Updating policies was consid-
ered an important task with a full review at approximate-
ly two-year intervals with policies having a clear issue
date and perhaps an expiry date. Concerns were ex-
pressed about the general lack of local audit underpin-
ning policy implementation.
Discussion around surgical prophylaxis raised a number
of issues including lack of evidence, an appearance of de-
fensive practice with regimes for one type of surgery be-
ing extrapolated to other surgical interventions and the
need to stimulate multicentre trials to answer questions
around effectiveness. In terms of ownership and target
audience for policy there was a clear steer to bring this
activity into the clinical governance agenda. It was
agreed that authors of policies should be responsible to
Drugs and Therapeutics committees in Trusts. The
group considering the content of policies had a majority
in favour of a mandatory status for antibiotic policies. A
full workshop report can be found as an Appendix, see
additional file 1: Appendix.
Discussion
The stimulus for this work was the Standing Medical Ad-
visory Committee (SMAC) [2] report and the linked
Health Service Circular [4]. The SMAC report states that
antimicrobial guidelines should be:
• Evidence based;
• State the date the document was created/revised;
• Contain information on antimicrobial, dose, frequency,
and length of course;
• Indicate strength of the evidence for the recommenda-
tion;
• Show local variation from national guidelines.
It was clear that some policies were the products of much
careful preparation, and could be excellent examples for
others who have no policies or are updating policies.
The variety in the presentations of antibiotic policies
came as a surprise. Some were clearly designed for ease
of use, with good quality printing, contents lists and
pocket sized. Some on a single sheet of A4 paper seemed
to be almost too simple. Others were larger, where the
policies were part of a hospital formulary or a compendi-
um of advice for hospital doctors. In some of the larger
documents, the antibiotic policy was presented in differ-
ent sections referring to different specialities. The au-
thors tried to put themselves in the position of doctors
starting at the hospital trust or in general practice, and
we preferred the pocket sized formats dedicated to anti-
biotics. The computer-based policy used in Winchester
could not be compared with the paper-based policies
used elsewhere, although it appeared to lie more at the
large and complex end of the spectrum of styles.
The trusts that were sharing policies had done so because
of mergers, either of the whole trusts or their microbiol-
ogy departments. In three health districts, there was a re-
lationship between the trust policies and the guidance
given to GPs. Greater collaboration between trusts, and
with health authorities would enable them to reduce the
labour in producing better policies and to lessen the con-
fusion for staff who move between hospitals. This view
was also clearly stated during the workshop with the con-
struction of the evidence base seen as an area requiring
collaboration at least at regional level and possibly na-
tionally.
Several trusts were in the process of updating their poli-
cies during this study, and some have subsequently sub-
mitted their latest drafts, this is reflected in the tables. It
is important that the date that a policy is written should
be prominent on the front cover, to avoid out-dated pol-
icies being used. Some trusts and health authorities reg-
ularly update their policies and this should be
encouraged as good practice.
Although some of the policies were conceived or written
before the current emphasis on evidence-based practice,
we were surprised that there were no policies which
statements that were backed with references. Examples
of easily available reviews are the guidance of meningo-
coccal treatment and prophylaxis [5], and prophylaxis
for asplenic patients [6]. These would have provided jun-
ior doctors with more detailed information to supple-
ment a pocket sized antibiotic policy. Given the wide
possibilities for surgical prophylaxis, supporting refer-
ences would be a valuable addition to the text. An evi-
dence base needs to be developed for surgical
prophylaxis that covers the vast number of potential per-
mutations when considering type of surgical interven-
tion, choice of antibiotic, timing and number of doses
among others. It was expected that all policies would
cover the common infections of the urinary and lower
respiratory tracts, and that there would be guidance on
the treatment of gastro-enteritis. Other infections, whichBMC Public Health (2001) 1:4 http://www.biomedcentral.com/1471-2458/1/4
were not reviewed in detail, but covered by most policies,
were pharyngeal and skin infections. Most policies gave
guidance on treating meningitis, but it is surprising that
only approximately 50% of the policies gave useful in-
structions on prophylaxis for the contacts of meningitis.
It is also surprising that there were some trust policies
that did not cover surgical prophylaxis and it is disap-
pointing that post-splenectomy prophylaxis was infre-
quently described.
The wide publicity on MRSA does not seem to have
greatly affected antibiotic policies as less than a half in-
cluded any statement on the subject. At the workshop
following the survey, it was pointed out that trusts may
have sections on MRSA in their infection control poli-
cies. MRSA policies should be explicitly mentioned in
trust antibiotic policies with appropriate cross-referenc-
es to other policies.
It might be argued that because antibiotics are generally
safe, dosage related to age is not an important issue.
However two examples where this is important concerns
ciprofloxacin which is contra-indicated below 12 years of
age and in pregnancy; also aminoglycoside dosage is af-
fected by age. It was evident that some policies had been
prepared with a premium placed on brevity. Neverthe-
less, it appears that the policies should give advice on
contra-indications and side effects, and on dosages ap-
propriate to very young children and the elderly. If poli-
cies are to be useful, they should aim to cover all the
important prescribing points.
One factor that merits further consideration is whether
policies should be mandatory or advisory. Whilst health
authority policies may have to be issued as guidance to
independent contractors such as general practitioners, it
appeared that trust policies were written more as advice
than as firm instruction. The development of primary
care trusts and clinical governance may lead to antibiotic
policies becoming more directive. If this is to be accepta-
ble, policies will have to be evidence based, and be able to
stand up to scrutiny. Some research has been carried out
on the place of antibiotics and attitudes towards such
policies. One US based study indicated that prescribers
preferred and adhered more closely to policies, which in-
volved an educational, rather than a restrictive approach
[7] . Spending on antimicrobial drugs represents approx-
imately 20% of drug expenditure in UK hospitals with
between a quarter and a third of all patients receiving an
antimicrobial agent whilst in hospital [8]. This overview
is not essentially about cost savings but there may be sav-
ings by managing antibiotics effectively [8]. The impor-
tant point is that the investment of developing sound
antibiotic policies including the associated educational
role has the potential to be cost effective.
While it is true that there is no absolute proof of a causa-
tive association between antibiotic use and resistance,
most authorities believe the association to be 'virtually
certain' [9].
In a working party report for the British Society for Anti-
microbial Chemotherapy [10] details of a much larger
survey were reported. The authors published an appen-
dix of nine minimum control measures. These cover
broadly similar issues but have generally not been imple-
mented. To the list, the need for an evidence base should
be added.
National guidelines have now been issued for primary
care [11] but the authors are not aware of a model policy
for secondary care.
Conclusions
There is clearly a wide variation across the structure and
content of antibiotic policies in the SouthEast. It is hoped
that this review will lead to a revision of policies to bring
them into line with current recommendations. The over-
all aim is to ensure that an effective range of antibiotics
is maintained. Policies alone will not achieve this, and
there needs to be local ownership by all prescribers with
effective monitoring to ensure that compliance with the
local antibiotic policy can be demonstrated.
Perhaps the most pressing need is the development of an
evidence base to underpin not only the content of poli-
cies but also their implementation and use. This needs to
be carried out by a suitable group nationally in order that
all may benefit.BMC Public Health (2001) 1:4 http://www.biomedcentral.com/1471-2458/1/4
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